A retrospective analysis of patients with gallbladder cancer: surgical treatment and survival according to tumor stage

Iago Justo, Alberto Marcacuzco, Oana-Anisa Nutu, Alejandro Manrique, Jorge Calvo, Óscar Caso, Félix Cambra, Álvaro García-Sesma and Carlos Jiménez-Romero

Unit of Hepato-Biliary-Pancreatic Surgery and Abdominal Organ Transplantation. Hospital Universitario 12 de Octubre. Department of Surgery. Faculty of Medicine. Complutense University of Madrid. Madrid, Spain

ABSTRACT

Introduction: gallbladder cancer is the most common biliary neoplasm and the sixth most common tumor of the digestive system. The disease has an ominous prognosis, with a 5-year survival rate of approximately 5%. It is usually diagnosed late and surgical resection is the only potential cure.

Methods: a retrospective study was carried out in 92 patients with a pathological diagnosis of gallbladder cancer from January 2000 to January 2016.

Results: the mean age of cases was 72 ± 11 years; 64 subjects were females and 28 were males. Symptoms at admission included abdominal pain (78%), anorexia (77%), nausea (76%) and jaundice (45%). Surgery was indicated in 92 (100%) patients and 59 (64%) underwent a curative/intent resection. The initial surgical procedures included simple cholecystectomy in 69 (75%) cases and extended cholecystectomy in eleven (11%) subjects. Rescue surgery was performed in 15 patients with tumor tissue in the cholecystectomy specimen; ten individuals underwent an R0 curative resection. Adjuvant therapy was administered in 30 (33%) patients. The median survival in our series was 12.5 months, with survival rates of 57%, 30% and 20% at one, three and five years, respectively.

Conclusion: to conclude, surgical treatment with a complete tumor resection should be considered for all patients, provided that their clinical status allows it.

Key words: Gallbladder cancer. Simple cholecystectomy. Extended cholecystectomy. Incidental gallbladder cancer.

INTRODUCTION

Gallbladder cancer (GBC) is the most common biliary neoplasm and the sixth most common tumor in the digestive system (1,2). Estimations suggest that 11,740 patients were diagnosed with gallbladder and bile duct cancer in the United States in 2017, which resulted in 3,830 deaths from GBC (1,3). The incidence varies according to geographic regions and ethnic/racial groups. The highest rates are reported in Chile, northeastern Europe, Israel, American Indians and Mexican Americans (2,4).

GBC has a poor prognosis, with a mean survival of six months and a 5-year survival rate of 5%. Risk factors for gallbladder cancer include cholelithiasis, obesity, gallbladder polyps > 1 cm, chronic gallbladder inflammation, environmental exposure and genetic alterations (4).

GBC is usually diagnosed taking into account the presence of a growth associated with regional adenopathies and distant metastases. However, 47% of these tumors are incidentally diagnosed following the examination of a cholecystectomy specimen (5). The incidence of gallbladder cancer in cholecystectomy specimens ranges from 0.2% to 3% (6-9).

Only a complete tumor resection (R0) offers a possibility of cure. However, the criteria for surgical resection are highly variable according to tumor stage. Surgical techniques range from simple cholecystectomy to right-side hepatec-
tomography. Therefore, surgery adjusted to tumor stage is the only therapy that has somewhat improved the mean survival to date. However, the 5-year survival rates are still very low.

The primary goal of the study was to analyze and describe the epidemiological, clinical and therapeutic characteristics of patients diagnosed with GBC. The secondary endpoint was to assess survival according to tumor stage and surgical treatment.

**MATERIAL AND METHODS**

A descriptive, retrospective analysis of patients with a pathological diagnosis of GBC from January 2000 to January 2012 was performed. A total of 92 cases of GBC were collected during this period. The medical records were reviewed of patients with histologically confirmed GBC that were recorded in the tumor registry. Demographic, clinical, laboratory, radiological and histological variables were collected. Furthermore, data regarding surgical procedure, chemotherapy and survival according to tumor stage were also collected. Staging was performed according to the American Joint Committee on Cancer (AJCC) TNM Classification, 7th edition (10).

Cases of suspected GBC (radiographic finding) or incidental GBC at histology were presented to a multidisciplinary committee (gastroenterologists, oncologists, radiologists and surgeons). The indications for surgery and adjuvant therapy were discussed for each patient. Similarly, the follow-up of patients that underwent an R0 resection was performed according to the hospital protocol. Regular controls were performed by oncologists and surgeons every three months during the first two years and every six months thereafter over five years.

The initial surgery was based on simple or extended cholecystectomy which included radical cholecystectomy (cholecystectomy plus 2-3-cm resection of the surrounding liver parenchyma and hepatic hilar lymphadenectomy), cholecystectomy plus hepatectomy (bisegmentectomy IVb-V) and hepatic hilar lymphadenectomy. A potentially curative surgery was indicated when imaging tests or prior surgery suggested the feasibility of a tumor-free resection (R0). Similarly, palliative surgery was performed to relieve GBC-related symptoms or to prevent complications when a complete resection was not possible, for instance, in cases of perforated cholecystitis, bile duct obstruction, etc.

With regard to patients with residual tumor after examination of the surgical specimen, rescue surgery was considered as follows: in stage T1a (tumor invasion of the lamina propria), simple cholecystectomy was envisaged as a curative treatment with no need for rescue surgery; in stage T1b (tumor invasion of muscle layer) and T2 (perimuscular invasion without extension beyond the serosa or to the liver), rescue surgery consisted of a radical cholecystectomy. Bisegmentectomy IVb-V was considered for patients with liver invasion by contiguity, whereas a right hepatectomy was performed in patients with extensive liver invasion and/or invasion of the right sided vessels or bile ducts with an R0 intent.

Disease-free survival was defined as the interval between GBC surgery and radiographic or histological relapse. Survival analysis was censored in December 2017 and all patients had at least one year of follow-up.

**Statistical analysis**

Absolute frequencies and relative frequencies were used to describe qualitative variables as percentages. Quantitative variables were expressed as a mean and standard deviation when the distribution was normal and as the median 25th and 75th percentile when the distribution was not normal. Quantitative variable normality was assessed with the Kolmogorov-Smirnov test.

The Chi-squared test or Fisher’s exact test was used to assess relationships between qualitative variables. Quantitative variable behavior was assessed for each independent variable using the Student’s t-test. Nonparametric tests were used when normality could not be assumed.

Patient survival was estimated using the actuarial or Kaplan-Meier method and survival rates were compared using the log-rank test. A p value < 0.05 was considered as statistically significant. Study data were collected and analyzed using the SPSS 17.0 software.

**RESULTS**

The mean age of cases was 72 ± 11 years, 64 (70%) patients were female and 28 (30%) patients were male. Relevant histories included blood hypertension (62%), diabetes (33%), smoking (22%) and drinking (11%). The main symptoms included abdominal pain (78%), nausea (58%), anorexia (55%) and jaundice (45%). Relevant laboratory data included a shift in liver function towards a predominantly cholestatic pattern. Furthermore, 40 (43%) patients had increased CEA levels and 53 (58%) had abnormal CA19.9 levels with a median of 52 U/ml (Table 1).

All patients underwent imaging tests, mainly abdominal ultrasound (93%) followed by abdominal computed tomography (CT) (41%). Imaging studies revealed cholelithiasis in 89 (97%) patients, intra- and/or extrahepatic bile duct dilatation in 40 (43%) patients, cholecystitis in 40 (43%) patients and vesicular polyps in nine (10%) patients.

Surgery was performed in all 92 patients; the primary indication was most frequently acute cholecystitis (43%) followed by cholelithiasis (37%) and a preoperative diagnosis of GBC (20%). Laparoscopy was used initially in 21 (23%) patients and led to a subsequent laparotomy in 12 cases. Surgical procedures performed as an initial surgery included (Fig. 1) simple cholecystectomy in 69 (75%) patients and cholecystectomy plus hepatectomy in eleven (12%) patients; the latter consisted of a bisegmentectomy IVb-V in ten cases and extended right hepatectomy in one case. Furthermore, eight patients underwent an exploratory laparotomy that revealed advanced disease. All cases underwent palliative surgery due to perforated acute cholecystitis (3) and bile duct obstruction (5). The pathological diagnosis was adenocarcinoma in 87 (95%) patients, adenosquamous carcinoma in two (2%), mucoepidermoid carcinoma in two (2%) and squamous-cell carcinoma in one (1%) patient.
Rescue surgery was performed in 12 (13%) patients and eight patients had a curative resection (R0) (radical cholecystectomy in three and bisegmentectomy IVb-V in five). The remaining patients (four) had unresectable metastatic disease (Table 2).

With regard to the T parameter of the TNM system, five patients were Tis, 14 were T1, 19 were T2, 32 were T3 and 22 were T4. With regard to the N parameter, 26 (28%) patients had node tumor involvement; the histology was negative in 41 (45%) cases and not assessable (Nx) in 25 (27%) cases. Furthermore, metastases (M1) were seen in 38 (41%) patients. Infiltration by contiguity was seen at the omentum (seven patients), duodenum (seven) and colon (two). In addition, eight (9%) patients had synchronous tumors (two prostate,
two colonic, one gastric, one renal, one meningioma, and one skin) and ten (11%) had metachronous tumors (three gastric, three colorectal, two breast, one ovarian, one prostate).

Adjuvant therapy was used in 30 (33%) patients; gemcitabine was administered in 16 subjects with unresectable tumors and gemcitabine plus cisplatin, in 14 subjects with previously resected tumors (Table 2).

Postoperative mortality (within 30 days) was 10% (nine patients). Four patients died due to metastatic disease and these cases had only undergone exploratory laparotomy as an initial surgery. Three patients died from biliary or hepatic sepsis; two patients, following simple cholecystectomy; one patient, after extended cholecystectomy. One patient died from liver failure after rescue surgery consisting of a right hepatectomy and one patient died from pneumonia after a simple cholecystectomy.

The median survival in our series was 12.5 months (0-96) and the survival rate after R0 surgery was 78%, 58.5% and 42% at one, three and five years, respectively. Furthermore, disease-free survival was 77.6%, 45.2% and 33.1% at one, three and five years, respectively (Fig. 2).

When analyzed according to TNM stage, survival was longer for patients with Tis-T1-T2 rather than T3-T4 (p ≤ 0.01) tumors. In addition, patients with stages 0, I and II survived longer than those with stages III and IV (Fig. 3).

**DISCUSSION**

Gallbladder cancer is a relatively rare condition in our setting, with a high mortality rate primarily due to the delayed diagnosis and the presence of tumor spread (11,12). Presentation symptoms are usually nonspecific and differen-

---

**Fig. 1. Surgical management of patients with GBC.**
A retrospective analysis of patients with gallbladder cancer: surgical treatment and survival according to tumor stage

Table 2. Histological characteristics treatments received of patients with gallbladder cancer

<table>
<thead>
<tr>
<th></th>
<th>Total n = 92</th>
<th>Tis n = 5</th>
<th>T1 n = 14</th>
<th>T2 n = 19</th>
<th>T3 n = 32</th>
<th>T4 n = 22</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>87 (95%)</td>
<td>5 (100%)</td>
<td>14 (100%)</td>
<td>19 (100%)</td>
<td>28 (88%)</td>
<td>21 (95%)</td>
</tr>
<tr>
<td>Adenosquamous</td>
<td>2 (2%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (6%)</td>
<td>0</td>
</tr>
<tr>
<td>Mucopidermoid</td>
<td>2 (2%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (6%)</td>
<td>0</td>
</tr>
<tr>
<td>Epidermoid</td>
<td>1 (1%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (5%)</td>
</tr>
<tr>
<td><strong>Differentiation grade</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>44 (48%)</td>
<td>5 (100%)</td>
<td>12 (86%)</td>
<td>11 (58%)</td>
<td>11 (34%)</td>
<td>5 (23%)</td>
</tr>
<tr>
<td>Moderately</td>
<td>26 (28%)</td>
<td>0</td>
<td>2 (14%)</td>
<td>5 (26%)</td>
<td>10 (31%)</td>
<td>9 (41%)</td>
</tr>
<tr>
<td>Poorly</td>
<td>22 (24%)</td>
<td>0</td>
<td>0</td>
<td>3 (16%)</td>
<td>11 (34%)</td>
<td>8 (36%)</td>
</tr>
<tr>
<td><strong>Nodes (N):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nx</td>
<td>25 (27%)</td>
<td>0</td>
<td>3 (21%)</td>
<td>1 (5%)</td>
<td>9 (28%)</td>
<td>12 (55%)</td>
</tr>
<tr>
<td>N0</td>
<td>41 (45%)</td>
<td>5 (100%)</td>
<td>11 (79%)</td>
<td>11 (58%)</td>
<td>12 (38%)</td>
<td>2 (9%)</td>
</tr>
<tr>
<td>N1</td>
<td>25 (27%)</td>
<td>0</td>
<td>0</td>
<td>7 (37%)</td>
<td>10 (31%)</td>
<td>8 (36%)</td>
</tr>
<tr>
<td>N2</td>
<td>1 (1%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (3%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Metastasis (M):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>54 (59%)</td>
<td>5 (100%)</td>
<td>14 (100%)</td>
<td>15 (79%)</td>
<td>18 (56%)</td>
<td>2 (9%)</td>
</tr>
<tr>
<td>M1</td>
<td>38 (41%)</td>
<td>0</td>
<td>0</td>
<td>4 (21%)</td>
<td>14 (44%)</td>
<td>20 (91%)</td>
</tr>
<tr>
<td><strong>Surgical treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial surgery</td>
<td>92 (100%)</td>
<td>5 (100%)</td>
<td>14 (100%)</td>
<td>19 (100%)</td>
<td>32 (100%)</td>
<td>22 (100%)</td>
</tr>
<tr>
<td>Simple cholecystectomy</td>
<td>69 (75%)</td>
<td>5 (100%)</td>
<td>12 (86%)</td>
<td>16 (84%)</td>
<td>27 (84%)</td>
<td>9 (41%)</td>
</tr>
<tr>
<td>Hepatectomy, segments IVb-V</td>
<td>11 (12%)</td>
<td>0</td>
<td>0</td>
<td>2 (11%)</td>
<td>5 (16%)</td>
<td>4 (18%)</td>
</tr>
<tr>
<td>Exploratory laparotomy</td>
<td>8 (9%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>8 (36%)</td>
</tr>
<tr>
<td>Radical cholecystectomy</td>
<td>4 (4%)</td>
<td>0</td>
<td>2 (14%)</td>
<td>1 (5%)</td>
<td>0</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Rescue surgery</td>
<td>12 (13%)</td>
<td>0</td>
<td>0</td>
<td>3 (16%)</td>
<td>8 (25%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Hepatectomy, segments IVb-V</td>
<td>5 (5%)</td>
<td>0</td>
<td>0</td>
<td>2 (11%)</td>
<td>3 (9%)</td>
<td>0</td>
</tr>
<tr>
<td>Exploratory laparotomy</td>
<td>4 (4%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3 (9%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Radical cholecystectomy</td>
<td>3 (3%)</td>
<td>0</td>
<td>0</td>
<td>1 (5%)</td>
<td>2 (6%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Cancer therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant</td>
<td>30 (33%)</td>
<td>0</td>
<td>1 (7%)</td>
<td>5 (26%)</td>
<td>16 (50%)</td>
<td>8 (36%)</td>
</tr>
<tr>
<td>Gemcitabine (unresectable cases)</td>
<td>16 (17%)</td>
<td>0</td>
<td>0</td>
<td>2 (11%)</td>
<td>6 (7%)</td>
<td>8 (36%)</td>
</tr>
<tr>
<td>Gemcitabine + cisplatin (resectable cases)</td>
<td>14 (15%)</td>
<td>0</td>
<td>1 (7%)</td>
<td>3 (16%)</td>
<td>10 (11%)</td>
<td>0</td>
</tr>
</tbody>
</table>

Serum carcinoembryonic antigen (CEA) and CA19.9 levels have been studied as screening markers, although they are nonspecific. CEA levels above 4 ng/ml have a specificity of 93% for the diagnosis of GBC compared to values in control subjects undergoing cholecystectomy for a benign biliary condition. However, the sensitivity is only 50% (15). Furthermore, elevated CA125, CA19.9, and CA242 levels have been reported in cases with distant lymph node metastasis (16). In our series, CA19.9 was the tumor marker that was most frequently elevated in GBC patients. With regard to the diagnostic approach used in our series, ultrasound was the most easily accessible and common initial test even though its yield rate for the initial diagnosis is not the highest among the various options available. The best imaging technique for GBC staging is contrast-enhanced CT, which may be supplemented by magnetic resonance (MR) cholangiography when biliary involvement is suspected (17). A relevant aspect of this condition is the advanced stage of the tumor at diagnosis. Thus, a low percentage of patients...
are eligible for curative intent surgery; the latter is estimated to be only 25% of patients and only 16% of these will be alive after five years (18). In our series, complete tumor resection was only achieved in 55% of patients. Furthermore, disease-free survival at five years was 33%, a rate similar to that reported in other series (19).

The surgical management of GBC has evolved over the last few decades, and extended resections have been introduced into clinical management that have improved patient survival. Thus, extended or radical surgery without residual tumor (R0) may be the treatment of choice. However, randomized and controlled studies to define the optimum management have been sparse due to the low incidence of this tumor.

According to the latest guidelines, GBC management is based on TNM staging; simple cholecystectomy is considered to be the treatment of choice for T1a (confined to the mucosa) tumors. With regard to the surgical approach (laparoscopic vs laparotomic), recent studies suggest that the laparoscopic route is equivalent to the classic approach, even providing better results (19). Similarly, extended cholecystectomy is not appropriate in this stage, nor does it increase survival. However, when the tumor has invaded the cystic duct resection margin, resection of the biliary tract should be considered. Furthermore, no reported studies recommend the use of lymphadenectomy for stage T1a. In our series, simple cholecystectomy was considered as the treatment of choice for stage T1a and regional lymphadenectomy was deemed unnecessary. There is a lot of debate with regard to the management of patients with stage T1b (muscle layer infiltration) and T2 (serosal invasion, not beyond) cancer. The current tendency in surgery is radical cholecystectomy (extending to 2-3 cm away from the liver bed) or segment IVb-V resection. Both are associated with regional lymphadenectomy (17). However, the benefit of these surgical procedures is the subject of much debate since they are associated with low survival and high morbidity-mortality rates, and often no evidence of disease is collected (20).
Extended liver bed resection, either alone or associated with bisegmentectomy IVb/V for T2 tumors, may be a surgical approach based on tumor location (21). The gallbladder has a peritoneal (inferior) aspect and a hepatic (superior) aspect, with anatomic differences between both. There is no serosa on the hepatic aspect as the bladder is attached to the liver by connective tissue, which may facilitate tumor invasion by contiguity. Therefore, surgical management may vary depending on tumor location (22,23). Survival is not affected by liver resection in patients with T2 tumors on the peritoneal side, which represents a relevant prognostic factor. However, recurrence rates are higher when the surgery is not associated with a liver resection in T2 tumors on the hepatic side. In our series, rescue surgery was considered for 16 patients with stage T2 tumors (after finding GBC in the histology study following simple cholecystectomy). Of these, surgery was not performed in 13 cases due to distant metastasis, significant comorbidity or patient refusal (Fig. 1). Therefore, one patient underwent a radical cholecystectomy and two patients underwent a bisegmentectomy IVb-V; the surgery was curative and residual disease was found in pathological specimens.

Most patients in our study had stage T3/T4 (59%) tumors and were diagnosed after simple cholecystectomy. Rescue surgery was subsequently performed. As recommended, patients with stage T3 tumors should undergo rescue surgery, except for cases with a relevant comorbidity or advanced disease. Furthermore, patients with T3/T4 and lymph node involvement (N+) should be candidates for neoadjuvant therapy (17).

Lymph node metastasis is a prognostic factor and incidence by stage has been reported as follows: 0-2.5% in T1a, 5-16% in T1b, 9-30% in T2, 39-72% in T3, and 67-80% in T4. However, there is no consensus regarding the extent of the lymphadenectomy in association with radical cholecystectomy. Its relevance for survival and staging is recognized and allows to differentiate standard lymphadenectomy (confined to the hepatoduodenal ligament) from extended lymphadenectomy (celiac trunk, interaorto-caval space, etc.), with improved survival in the latter (24,25). In our series, regional lymphadenectomy was performed in all patients undergoing an extended cholecystectomy. Furthermore, patients without lymph node involvement (N0) have higher survival rates (p < 0.05) compared to subjects with node involvement (N+); at least 4 lymph nodes should be analyzed in order to rule out nodal involvement (26).

With regard to biliary tract resection, the prognostic value remains unknown, except in cases where its indication is clear, such as tumor infiltration of the cystic duct or common bile duct with no distant metastases (27). There are few experimental studies available with regard to adjuvant chemotherapy after tumor resection. The phase-III ABC-02 study (cisplatin + gemcitabine vs cisplatin alone) randomized clinical trial has shown a benefit for advanced biliary or metastatic tumors (28). Adjuvant therapy resulted in improved survival, even in patients with stage T3/T4 disease, nodal involvement and R1 resection (29). Radiotherapy is also increasingly used as it significantly reduces local recurrence rates and increases short-term survival (30). In our series, 30 patients received adjuvant therapy which was associated with radiotherapy in five patients.

A major bias in our study is its retrospective nature, which limited data collection and analysis. However, we believe that this review may contribute to the management of patients with this condition. To conclude, gallbladder cancer is an uncommon condition that may be incidentally diagnosed during the pathological analysis after cholecystectomy. Surgical management with complete (R0) tumor resection should be considered for all patients, provided their clinical status allows it. Therefore, treatment should be individualized for each patient.

REFERENCES


